Advertisement

Erratum

    Published:November 03, 2021DOI:https://doi.org/10.1016/j.jtho.2021.10.006
        In the course of analyzing the five-year data from the ECLIPSE study, we became aware of an error in the interim analysis publication, “Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis at 1 Year J Thorac Oncol. 2015;10:1468-1474. In the analyses of local tumor control, four patients had missing assessments at certain timepoints and, instead of being excluded, they were coded to have a partial response and included in the summary statistics. This error was caught in the updated analyses, and the values of those four patients who were miscoded as having a partial response were excluded. In doing so, the denominator decreased because these patients did not have an assessment.
        While this error does not affect any tables or figures, it does affect some of the results reported in the manuscript text. Specifically, the following sentence should be amended:
        “Overall local tumor control after ablation at the 12-month analysis, for combined stable disease, partial, and complete response, was seen in 49 of 52 metastases (94.2%) and 32 of 35 patients (91.4%).”
        The corrected sentence is: “Overall local tumor control after ablation at the 12-month analysis, for combined stable disease, partial, and complete response, was seen in 45 of 48 metastases (93.8%) and 29 of 32 patients (90.6%).”
        After discussion with our statistical team, we believe that this correction does not affect any of the other results, discussion, or conclusions presented within the manuscript as published.

        Linked Article